Stay updated with breaking news from Head External. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Santhera Pharmaceuticals (SIX: SANN) announces preliminary 2021 financial results and operational progress made. The Company is on track to start a rolling NDA submission for vamorolone in DMD at the end of March. With a cash balance of CHF 18 million (February 28, 2022), the announced increase of share issuances ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Initiation of rolling
Santhera Signs Gene Therapy Agreement with SEAL Therapeutics Pratteln, Switzerland, February 28, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy. Santhera has entered into an...
Pratteln, Switzerland, February 28, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy.
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Completes Repayment of 2017/22 Convertible Bonds